New treatment options for advanced hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer have improved care, making it more effective and tailored to individual needs. This subtype, which depends on estrogen to grow, represents most advanced breast cancer cases. Patients with metastatic disease—where cancer has spread beyond the breast—usually receive first-line treatment combining hormone therapy with a CDK4/6 inhibitor to control the disease.
Dhvani Thakker, director of women’s medical oncology at Mount Sinai South Nassau, said the goal is to help patients live longer and maintain quality of life. The right approach depends on factors like symptoms, disease burden, and prior therapies, as Madhurima Anne, director of hematology/oncology at Hackensack Meridian Ocean University Medical Center, explained.
How first-line treatment works
The standard first-line treatment for advanced HR+/HER2- breast cancer often pairs an aromatase inhibitor with a CDK4/6 inhibitor. Aromatase inhibitors reduce estrogen levels, while CDK4/6 inhibitors block a pathway that helps cancer cells grow. This combination has been shown to improve response rates and help patients live longer.
Over time, resistance to hormone therapy can develop. When that happens, other treatments become necessary. The FDA has approved three CDK4/6 inhibitors for this subtype, each with distinct benefits and side effects.
Related: MD Anderson leads cancer hospital rankings
- Ribociclib (Kisqali): Offers the strongest overall survival benefit in first-line treatment but requires monitoring for liver function and heart rhythm changes.
- Abemaciclib (Verzenio): Works well in second-line settings but may cause severe diarrhea and blood clots.
- Palbociclib (Ibrance): The only CDK4/6 inhibitor without proven survival benefits, though it remains an option for patients who cannot tolerate the others.
No direct comparisons exist between these drugs, so the choice depends on a patient’s health and medical history.
Testing for mutations guides next steps
When first-line treatment stops working, doctors test tumors for genetic mutations. These tests reveal why the cancer resists treatment and help determine the next approach.
Dr. Anne noted that patients with metastatic HR+/HER2- breast cancer are typically screened for PIK3CA, AKT1, PTEN, and ESR1 mutations. An ESR1 mutation, for example, often explains why cancer stops responding to aromatase inhibitors. Those with PIK3CA mutations may receive endocrine therapy alongside drugs targeting the PI3K/AKT pathway, such as alpelisib (Piqray).
Selective estrogen receptor degraders (SERDs) provide another option, particularly for tumors with ESR1 mutations. Originally available only as an injection (fulvestrant), newer oral versions like elacestrant (Orserdu) are now approved for metastatic cases resistant to first-line therapies.
Related: Strength training lowers women’s heart attack risk 44%
These advances do not guarantee uniform responses. Precision medicine tailors treatment plans to individual biology, but not every mutation has a targeted therapy. Some patients may try multiple options before finding an effective one.
Questions for your oncologist
Patients should prepare for appointments by asking key questions. Dr. Anne and Dr. Thakker suggest:
- What first-line treatment do you recommend, and why?
- What side effects should I expect?
- What monitoring will I need?
- Has my tumor been tested for PIK3CA, AKT1, PTEN, or ESR1 mutations? How will those results affect my care?
- How will we measure whether treatment is working?
- Am I eligible for clinical trials?
The expanding range of treatments offers more hope than ever. Standard therapies already help many patients live longer with better quality of life, and ongoing research continues to refine approaches. For now, the best strategy involves clear communication with an oncologist to align treatment with personal goals and biology.
Leave a Reply